PURPOSE: Radical prostatectomy is potentially curative in patients with clinically localized prostate cancer. However, biochemical recurrence affects 15% to 30% of men who undergo radical prostatectomy. We previously reported the prognostic potential of PITX2 gene promoter methylation using conventional assays. In the current study we validated PITX2 methylation status as a biochemical recurrence predictor after radical prostatectomy using a novel microarray based platform in a multi-institutional setting. MATERIALS AND METHODS: PITX2 methylation status was assessed in formalin fixed, paraffin embedded prostatectomy tumor tissue samples from 476 patients from a total of 4 institutions on customized EpiChip PITX2 microarrays. Associations between PITX2 methylation and biochemical recurrence were assessed using the log rank test and Cox regression controlling for prostate cancer features. RESULTS: On multivariate analysis men with high methylation status were at significantly higher risk for biochemical recurrence than those with low methylation status (HR 3.0, 95% CI 2.0-4.5, p <10(-5)). The biochemical recurrence-free survival rate 5 years after surgery was 85% and 61% in the low and high methylation groups, respectively. In men with pathological Gleason 7 tumors the relative risk of biochemical recurrence was twice as high for high than for low PITX2 methylation (HR 2.0, 95% CI 1.2-3.3, p = 0.005). CONCLUSIONS: PITX2 methylation status assessed by EpiChip PITX2 identifies patients with prostate cancer who are most likely to have biochemical recurrence. This test independently adds to the prognostic information provided by standard clinicopathological analysis, improving prostatectomy case stratification into those at high and low risk for biochemical recurrence. This new clinical tool would be of particular benefit to assess intermediate risk cases (Gleason 7) in which risk stratification remains a challenge. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PURPOSE: Radical prostatectomy is potentially curative in patients with clinically localized prostate cancer. However, biochemical recurrence affects 15% to 30% of men who undergo radical prostatectomy. We previously reported the prognostic potential of PITX2 gene promoter methylation using conventional assays. In the current study we validated PITX2 methylation status as a biochemical recurrence predictor after radical prostatectomy using a novel microarray based platform in a multi-institutional setting. MATERIALS AND METHODS:PITX2 methylation status was assessed in formalin fixed, paraffin embedded prostatectomy tumor tissue samples from 476 patients from a total of 4 institutions on customized EpiChip PITX2 microarrays. Associations between PITX2 methylation and biochemical recurrence were assessed using the log rank test and Cox regression controlling for prostate cancer features. RESULTS: On multivariate analysis men with high methylation status were at significantly higher risk for biochemical recurrence than those with low methylation status (HR 3.0, 95% CI 2.0-4.5, p <10(-5)). The biochemical recurrence-free survival rate 5 years after surgery was 85% and 61% in the low and high methylation groups, respectively. In men with pathological Gleason 7 tumors the relative risk of biochemical recurrence was twice as high for high than for low PITX2 methylation (HR 2.0, 95% CI 1.2-3.3, p = 0.005). CONCLUSIONS:PITX2 methylation status assessed by EpiChip PITX2 identifies patients with prostate cancer who are most likely to have biochemical recurrence. This test independently adds to the prognostic information provided by standard clinicopathological analysis, improving prostatectomy case stratification into those at high and low risk for biochemical recurrence. This new clinical tool would be of particular benefit to assess intermediate risk cases (Gleason 7) in which risk stratification remains a challenge. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: T Powrózek; P Krawczyk; M Nicoś; B Kuźnar-Kamińska; H Batura-Gabryel; J Milanowski Journal: Clin Transl Oncol Date: 2015-08-27 Impact factor: 3.405
Authors: Shanshan Zhao; Milan S Geybels; Amy Leonardson; Rohina Rubicz; Suzanne Kolb; Qingxiang Yan; Brandy Klotzle; Marina Bibikova; Antonio Hurtado-Coll; Dean Troyer; Raymond Lance; Daniel W Lin; Jonathan L Wright; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Janet L Stanford Journal: Clin Cancer Res Date: 2016-06-29 Impact factor: 12.531
Authors: Sebastian Meller; Lisa Zipfel; Heidrun Gevensleben; Jörn Dietrich; Jörg Ellinger; Michael Majores; Johannes Stein; Verena Sailer; Maria Jung; Glen Kristiansen; Dimo Dietrich Journal: Epigenetics Date: 2016-09-30 Impact factor: 4.528
Authors: Dimo Dietrich; Oliver Hasinger; Lionel L Bañez; Leon Sun; Geert J van Leenders; Thomas M Wheeler; Chris H Bangma; Nicolas Wernert; Sven Perner; Stephen J Freedland; John M Corman; Michael M Ittmann; Amy L Lark; John F Madden; Arndt Hartmann; Philipp Schatz; Glen Kristiansen Journal: J Mol Diagn Date: 2012-12-22 Impact factor: 5.568
Authors: I Vela; C Morrissey; X Zhang; S Chen; E Corey; G M Strutton; C C Nelson; D L Nicol; J A Clements; E M Gardiner Journal: Clin Exp Metastasis Date: 2013-10-26 Impact factor: 5.150
Authors: Christa Haldrup; Anne-Sofie Lynnerup; Tine Maj Storebjerg; Søren Vang; Peter Wild; Tapio Visakorpi; Christian Arsov; Wolfgang A Schulz; Johan Lindberg; Henrik Grönberg; Lars Egevad; Michael Borre; Torben Falck Ørntoft; Søren Høyer; Karina Dalsgaard Sørensen Journal: Mol Oncol Date: 2016-02-09 Impact factor: 7.449